Business Wire

IFF Achieves Key 2020 Sustainability Goals

Share

IFF (NYSE:IFF) today announced the achievement of key 2020 sustainability goals that were set at the launch of the Company’s sustainability program in 2010. During that time, IFF met and surpassed its original intensity-based targets for three environmental goals, resulting in a reduction in its greenhouse gas (GHG) emissions, water withdrawal and hazardous waste generation per metric ton of production by -42.6%, -67.1% and -41% below 2010 levels, respectively. IFF has also achieved its 2020 goal to have 100% of the palm oil used in its products be certified according to the Roundtable on Sustainable Palm Oil (RSPO) Mass Balance Supply Chain Model.

These and other milestones are captured in its latest Sustainability Report, “For a Better World,” which is published today. The title references the Company’s purpose – Applying science and creativity for a better world – a clear and bold aspiration that inspires everyone at IFF to push past traditional boundaries and to be a force for a better and more sustainable future.

Andreas Fibig, IFF Chairman and CEO, said: “Although 2020 was a year unlike any we could have predicted, I am proud to say that IFF rose to the challenges we faced and remained steadfast in our commitments to people and planet – further strengthening our sustainability leadership position. As pleased as we are with our results, the solemnity of the urgent challenges that remain – from the climate emergency and nature loss to mounting inequality – compels us to do more, to do better. As we work toward a better world with the continued support of our employees, customers, suppliers and other partners, we look forward to building on our successes in 2020 and achieving even more ambitious environmental, social and governance (ESG) targets in the future.”

In addition to highlighting progress against IFF’s 2020 environmental goals, the report also covers the Company’s achievements throughout the business in leveraging sustainable practices within its global footprint. For example:

  • Externally recognized for sustainability leadership, including being named to the Dow Jones Sustainability Indices, FTSE4Good Index Series, Euronext Vigeo World 120 Index and CDP A list, as well as receiving the EcoVadis platinum sustainability rating
  • Continued its commitment to climate action by advancing on its Science Based Target to reduce absolute GHG emissions by 19.7% since 2015; powering 52% of its operations’ electricity requirements with renewable energy; and reporting for the first time in alignment with the recommendations of the Task Force on Climate-related Financial Disclosures (TCFD)
  • Expanded safety culture and training, resulting in a reduction in its lost time incident rate of 46% from the prior year
  • Launched industry-leading blockchain technology as a tool for ensuring ingredient traceability in the vanilla supply chain in Madagascar
  • Further embedded its commitment to circular design across its business, including by launching the Upcycled Extracts Collection, an ingredients portfolio made from several types of side-streams from its own processing that would otherwise be discarded
  • Strengthened its commitment to diversity, equity & inclusion and was the first company to earn Economic Dividend for Gender Equality (EDGE) Move level certification globally

Dr. Greg Yep, IFF’s Chief Research & Development, Global Integrated Solutions and Sustainability Officer, said, “Looking back over ten years of sustainability at IFF, we are thrilled with what we have been able to achieve. Following the merger with DuPont Nutrition & Biosciences, the decade ahead not only marks the next phase of IFF’s sustainability journey, but also represents a pivotal window of opportunity. By focusing on sustainable innovation, circular design and integrated solutions, we look forward to leveraging our newly expanded capabilities to help address the world’s greatest sustainable development challenges.”

To read IFF’s 2020 Sustainability Report, visit iff.com/responsibilities and use #DoMoreGoodxIFF to follow the conversation on its social channels.

Webcast

A live webcast to discuss the Company’s 2020 sustainability results and 2021 outlook will be held on May 20, 2021 at 9:00 a.m. ET. Mr. Fibig and Dr. Yep will be joined by Chief Investor Relations & Communications Officer Michael DeVeau; and Vice President, Global Sustainability & EHS Kip Cleverley, who will share updates on IFF’s key ESG metrics, goals and sustainability strategy. The webcast and accompanying slide presentation may be accessed on the Company’s Investor Relations website at ir.iff.com.

Investors and analysts are invited to participate by phone by calling 1-866-342-8591 from the United States and 1-203-518-9713 from other locations. The access code for the conference call is IFF0520 and a listen-only webcast will be available at ir.iff.com. For those unable to listen to the live webcast, a recorded version will be made available on the Company’s website approximately one hour after the event.

Welcome to IFF

At IFF (NYSE: IFF), an industry leader in food, beverage, scent, health and biosciences, science and creativity meet to create essential solutions for a better world – from global icons to unexpected innovations and experiences. With the beauty of art and the precision of science, we are an international collective of thinkers who partners with customers to bring scents, tastes, experiences, ingredients and solutions for products the world craves. Together, we will do more good for people and planet. Learn more at iff.com, Twitter, Facebook, Instagram, and LinkedIn.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Michael DeVeau
Chief Investor Relations & Communications Officer
212.708.7164
Michael.DeVeau@iff.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Pimicotinib Approved as Systemic Treatment in China for Tenosynovial Giant Cell Tumor22.12.2025 10:00:00 EET | Press release

Merck, a leading science and technology company, announced today that following Priority Review, the China National Medical Products Administration (NMPA) has approved pimicotinib for the treatment of adult patients with symptomatic tenosynovial giant cell tumor (TGCT) for which surgical resection will potentially cause functional limitation or relatively severe morbidity. Pimicotinib, a colony stimulating factor-1 receptor (CSF-1R) inhibitor developed by Abbisko Therapeutics Co., Ltd., Shanghai, China, is the first Chemical Drug Class 1 approved in China for the treatment of TGCT. “We are continuing to deliver on our commitment to improving the lives of patients with rare tumors with this first-in-the-world regulatory approval of pimicotinib,” said Danny Bar-Zohar, CEO Healthcare and Member of the Executive Board of Merck. “This approval is a significant step forward in further strengthening our leadership in rare tumors, while offering patients the opportunity to change the course of

Incyte Japan Announces Approval of Minjuvi ® (tafasitamab) in Combination with Rituximab and Lenalidomide for the Treatment of Relapsed or Refractory Follicular Lymphoma22.12.2025 09:44:00 EET | Press release

Incyte Biosciences Japan G.K. today announced approval from Japan's Ministry of Health, Labour and Welfare (MHLW) for Minjuvi® (tafasitamab) in combination with rituximab and lenalidomide for adult patients with relapsed or refractory follicular lymphoma (2L+ FL). “Today's approval of Minjuvi in combination with rituximab and lenalidomide marks a significant milestone as the first dual-targeted CD19 and CD20 immunotherapy combination for relapsed or refractory FL in Japan,” said Yasuyuki Ishida, General Manager, Incyte Biosciences Japan. “By improving progression-free survival, Minjuvi offers a chemotherapy-free option for eligible patients with relapsed or refractory disease. This approval underscores our commitment to bridging critical treatment gaps to patients and families affected by this challenging disease in Japan.” The approval is based on the pivotal Phase 3 inMIND trial, which enrolled 654 adult patients, including patients based in Japan. The study demonstrated that Minjuvi

Incyte Japan Announces Approval of Zynyz ® (retifanlimab) for the First-Line Treatment of Advanced Anal Cancer22.12.2025 09:42:00 EET | Press release

Incyte Biosciences Japan G.K. today announced the Japan Ministry of Health, Labour and Welfare (MHLW) approval of Zynyz® (retifanlimab) in combination with carboplatin and paclitaxel (platinum-based chemotherapy) for the first-line treatment of advanced squamous cell carcinoma of the anal canal (SCAC). "Today's approval marks a significant milestone for patients with advanced anal cancer in Japan – the MHLW’s approval of Zynyz as the first and only first-line treatment for SCAC," said Yasuyuki Ishida, General Manager, Incyte Biosciences Japan G.K. "By offering combination therapy with chemotherapy, Zynyz provides a vital new path forward for patients facing this challenging disease, addressing a significant unmet need in cancer care for patients with SCAC and their families." The approval was based on data from the Phase 3 POD1UM-303/InterAACT2 trial evaluating Zynyz in combination with platinum-based chemotherapy (carboplatin-paclitaxel) in adult patients with metastatic or inoperable

GBC AG Analyst Coverage Report on Mexedia S.p.A. Società Benefit Completed and Published22.12.2025 09:30:00 EET | Press release

Regulatory News: Mexedia S.p.A. Società Benefit (Euronext Growth Paris: ALMEX, ISIN IT0005450819) (“Mexedia” or the “Company”) informs that the analyst coverage report prepared by GBC AG – one of the leading independent financial research firms in Germany –, developed within an issuer-sponsored research framework, has been completed and is now publicly available. The report follows the re-initiation of analyst coverage by GBC AG previously communicated by the Company and is based exclusively on publicly available information. The content, assumptions and conclusions of the report are solely attributable to the analyst. The GBC AG analyst coverage report is available on the Company’s official website at the following address: https://mexedia.com/en/financial-statements-and-reports/ and on the analyst’s website. Daniel Gilcher, Chief Financial Officer of Mexedia S.p.A. Società Benefit, stated: “The completion and publication of the analyst coverage report by GBC AG represents the conclus

Hisense Joins HEVC Advance Patent Pool22.12.2025 04:06:00 EET | Press release

Access Advance LLC, the global leader in video codec patent pool licensing, today announced that Hisense Group Holdings Co., Ltd. has joined the HEVC Advance Patent Pool as a Licensee. Hisense joins the recent additions to the Access Advance patent pools, including Xiaomi, MSI, Transsion, and expanded relationships with Huawei, HP and Sharp. Hisense, headquartered in Qingdao, China, is one of the world's largest television manufacturers, with a global presence spanning Asia, Europe, the Americas, and beyond. The company's products reach consumers in more than 160 countries and regions worldwide. "We are pleased to welcome Hisense to the HEVC Advance Patent Pool," said Peter Moller, CEO of Access Advance. "This agreement is the result of extensive engagement between our teams over a considerable period of time. Hisense's decision to join the pool reflects a recognition that transparent, efficient licensing solutions benefit both innovators and implementers across the video technology ec

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye